YWYu-Fen Wang

Yu-Fen Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yu-Fen Wang has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Enlarged vestibular aqueduct concomitant with endolymphatic hydrops

    by Po-Yu Chen, Yu-Fen Wang, Yi-Ho Young

    Enlarged vestibular aqueduct (EVA) is one of the most common inner ear anomalies associated with sensorineural hearing loss (SNHL) in childhood. This study aimed to investigate the prevalence of EH in patients with large vestibular aqueduct syndrome (LVAS). A total of 20 patients with congenital SNHL underwent an inner ear test battery aligned with Hydrops MRI. Among them, 7 patients (unilateral involvement in 2 and bilateral involvement in 5, totaling 12 ears) with LVAS were enrolled. Abnormality rates across the inner ear test battery showed a significantly decreasing order, moving from audiometry (100%), cervical vestibular-evoked myogenic potential (VEMP) test (92%), caloric test (67%), to the ocular VEMP test (58%), which did not parallel with the declining trend of abnormality rate in Meniere's disease. Hydrops MRI demonstrated EH in 4 (57%) of 7 LVAS patients, comprising 5 ears in the cochlea and 4 ears in the vestibule. All patients received supportive treatment except one patient who underwent sac and shunt surgery, which resulted in profound deafness and recurrent postoperative vertigo. Hydrops MRI enables the simultaneous identification of EVA and EH. In this study, 57% of LVAS patients were found to have concomitant EH.

  • Profound sensorineural hearing loss in ears with endolymphatic hydrops

    by Tzu-Jui Lien, Chun-Nan Chen, Yu-Fen Wang, Yi-Ho Young

    Recently, Hydrops MRI has unexpectedly identified endolymphatic hydrops (EH) in patients presenting with profound sensorineural hearing loss (SNHL), highlighting a discrepancy that prompted further investigation. This study aimed to elucidate the mechanism of profound SNHL in ears with EH. Six (3%) of 184 patients with positive EH on Hydrops MRI presented with profound SNHL. Three of 6 patients had been previously diagnosed as Meniere's disease, and 4 patients were compromised hosts. All patients underwent an inner ear test battery followed by Hydrops MRI. The prevalence of EH at the cochlea and vestibule was identified in 67% and 42% of the ears, respectively. Three (50%) out of 6 patients experienced a short interval of 1-2 months between the onset of profound SNHL in both ears, which was associated with superimposed infection. In contrast, another three patients (50%) had a longer interval of 5-8 years, attributed to delayed EH. Profound SNHL in ears with EH suggests two potential mechanisms: a short interval (1-2 months) between onset in both ears points to a pre-existing hydrops ear further compromised by a superimposed infection, whereas a longer interval (5-8 years) indicates the development of delayed EH.


  • The long-term outcome of Meniere’s disease patients following sac and shunt operation assessed by Hydrops MRI

    by Hong-Yu Yan, Yu-Fen Wang, Yi-Ho Young

    Purpose The aim of this study was to evaluate the long-term outcome of Meniere’s disease (MD) patients who had previously undergone sac and shunt operation using Hydrops MRI for assessment. Methods A total of 17 unilateral MD patients who had previously undergone sac and shunt operation underwent an inner ear test battery, followed by Hydrops MRI. The 34 ears were classified into two groups. Group A consisted of 17 operated ears, which were further subdivided into Group A1 (with endolymphatic hydrops, EH), and Group A2 (without EH). In contrast, Group B comprised 17 non-operated (opposite) ears including Group B1 (with EH) and Group B2 (without EH). Results More than 70% MD patients continued to experience the Meniere’s triad of symptoms, even long-term (20 years) after surgery. A significantly decreasing sequence in the abnormality rates of the inner ear test battery was noted in Group A1 + B1, whereas no such declining trend was noted in Group A2 or B2. The prevalence of EH on operated ears demonstrated EH at the cochlea (65%), saccule (53%), and utricle (53%). Additionally, EH was also identified on non-operated ears, with a prevalence of 24% at the cochlea, and 12% at the saccule and utricle. Conclusion Using Hydrops MRI, this study found a 65% prevalence of cochlear EH on operated ears over a long-term period after surgery. This, coupled with a 70% prevalence of episodic vertigo, suggests that sac and shunt operation may not effectively alleviate EH.


  • Correlating audiological results with location of intracochlear schwannoma assessed by routine and Hydrops MRI

    by Yen-Ting Guo, Yu-Fen Wang, Yi-Ho Young

    Whether an intracochlear schwannoma (ICS) concomitant with endolymphatic hydrops (EH) remains unclear. This study had two objectives: first, to correlate the location of ICS with audiological results using routine MRI; and second, to determine whether an ICS is associated with EH using Hydrops MRI. Four cases with ICS demonstrated by routine MRI underwent an inner ear test battery, followed by 3 T Hydrops MRI. Audiometry revealed total deafness in 2 patients, flat-type hearing loss in one and 2 kHz dip type hearing loss in 1. Routine MRI demonstrated an ICS at cochlear basal turn in 3, and cochlear middle turn in 2 (one case showed ICS at the basal and middle turns). Correlating audiological results with the location of ICS suggests that hearing deterioration may be associated with affected cochlear turn. Hydrops MRI identified Grade II cochlear EH in two ICS patients with vertigo, but not in another two ICS patients without vertigo. For an ICS patient with vertiginous episode, routine MRI along with Hydrops MRI may help identify both the ICS and EH, simultaneously. A 'wait and scan' approach, which includes routine MRI along with Hydrops MRI, is recommended for the follow-up of ICS patients.

  • Open Access

    Idiopathic Intracranial Hypertension

    by Chun-Chieh Huang, Yu-Fen Wang

    Idiopathic Intracranial Hypertension

  • Detecting endolymphatic hydrops in patients with cranial nerve VIII schwannoma using hydrops MR examination

    by Ling-Chen Meng, Yu-Fen Wang, Yi-Ho Young

    Purpose This study utilized Hydrops MRI in patients with cranial nerve (CN) VIII schwannoma to assess the concomitance with endolymphatic hydrops (EH), aiming to elucidate the mechanism of hydrops formation in these patients. Methods Twenty-six patients diagnosed as CN VIII schwannoma including vestibular schwannoma (VS) in 24 and intracochlear schwannoma (ICS) in 2 were enrolled. Fifteen patients received radiosurgery and 11 patients opted for a wait-and-scan approach. All patients underwent an inner ear test battery, followed by Hydrops MRI. Based on Hydrops MRI, 6 patients (23%) with positive EH were assigned to Group A, while the other 20 patients showing negative EH were assigned to Group B. Results The abnormality rates of inner ear test battery in Group A ran from the audiometry (100%), cervical vestibular-evoked myogenic potential (cVEMP) test (83%), ocular VEMP (oVEMP) test (67%) to the caloric test (33%), exhibiting a significantly declining sequence. This declining sequence is consistent with the decreasing order in the prevalence of EH from the cochlea (83%), saccule (50%) to utricle (50%). However, Group B did not show such decreasing trend, indicating that Groups A and B did not share the common mechanism. The mean tumor size prior to radiosurgery was 1.91 ± 0.89 cm, which significantly reduced to 1.53 ± 0.60 cm at a mean interval of 6 years following radiosurgery. In contrast, tumor size remained unchanged in those opted for a wait-and-scan approach. Conclusion It is recommended to utilize Hydrops MRI for patients with CN VIII schwannoma during annual follow-up, particularly those experienced episodic vertigo and/or deteriorated hearing. The Hydrops MRI can not only monitor tumor size, but also detect the presence of EH, so as to guide treatment decision.


  • Open Access

    Abstract 1026: The costs of waiting to get treated for new AML patients: Medical expenditures, mortality rate, and length of hospital stay

    by Kang Lin Hsieh, Bor-Sheng Ko, Xiaoqian Jiang, Teng-Jen Chang, Yu-Fen Wang

    Introduction: We studied the association of waiting time from diagnostic Acute Myeloid Leukemia (AML) tests to initial treatment and medical expenditures, length of hospitalization, and survival rates for new AML patients. Method: We extracted 3,976 new AML patients from Optum’s de-identified Clinformatics࣪ Data Mart Database, a data warehouse of adjudicated commercial and medicare advantage claims. Their waiting days from standard diagnostic testings to the initial AML-specific treatment as the risk factor. Medical expenditures occurring within 6 months, 1 year, and 2 years after the index AML diagnosis was measured for the patients’ financial wellbeing, along with the survival rate and the length of hospital stay. We compared these outcomes for patients falling in each waiting time category. Different types of expenditures, including inpatient and outpatient costs for patients with different waiting lengths were compared. Results: For patients with moderate lengths of waiting time, medical expenditure and mortality rate increases and length of hospital stay decreased with waiting time. Within 2 years after the index AML diagnosis, the average expenditures per day goes from $4,803 for patients waiting for 0-2 days to $7,489 for patients waiting for 1-2 weeks, while the survival rate goes from 42.8% to 28.1% and the average length of stay goes from 45.6 days to 35.0 days. The increment in medical expenditure is mostly accounted for by outpatient costs, but is off-set by inpatient costs. The patterns for medical expenditure and survival rate reverse as waiting time becomes severe (3-4 weeks). Similar reverse is not observed for length of stay. Conclusion: The waiting time between AML diagnostic tests and initial treatments is associated with higher medical expenditure and higher mortality rate for moderate waiters. Our findings suggest that reducing waiting time has strong potential in improving AML patients’ survival and financial sustainability. Medical expenditure, survival rate, and length of hospital stay within 2 years by waiting time Medical expenditure per day ($) 2-yr Survival rate (%) Length of hospital stay (days) 28d 2224 51.0 35.0 Citation Format: Kang Lin Hsieh, Bor-Sheng Ko, Xiaoqian Jiang, Teng-Jen Chang, Yu-Fen Wang. The costs of waiting to get treated for new AML patients: Medical expenditures, mortality rate, and length of hospital stay [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1026.